Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $273,980.00 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the sale, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. The trade was a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Eben Tessari also recently made the following trade(s):

• On Monday, January 13th, Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00.

Kiniksa Pharmaceuticals Stock Up 0.5 %

KNSA opened at $19.74 on Friday. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $16.56 and a twelve month high of $28.15. The company has a 50-day moving average price of $19.82 and a 200 day moving average price of $22.89. The company has a market cap of $1.43 billion, a PE ratio of -140.99 and a beta of 0.32.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Braidwell LP raised its position in shares of Kiniksa Pharmaceuticals by 40.6% during the 3rd quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock worth $72,334,000 after purchasing an additional 836,210 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Kiniksa Pharmaceuticals by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company’s stock worth $15,262,000 after purchasing an additional 29,300 shares during the last quarter. Parkman Healthcare Partners LLC grew its stake in Kiniksa Pharmaceuticals by 16.7% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock valued at $18,874,000 after acquiring an additional 108,102 shares in the last quarter. FMR LLC grew its stake in Kiniksa Pharmaceuticals by 36,925.0% during the 3rd quarter. FMR LLC now owns 696,810 shares of the company’s stock valued at $17,413,000 after acquiring an additional 694,928 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its stake in Kiniksa Pharmaceuticals by 8.2% during the 3rd quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company’s stock valued at $16,234,000 after acquiring an additional 49,000 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Wall Street Analysts Forecast Growth

KNSA has been the subject of a number of analyst reports. Evercore ISI upped their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Wedbush reiterated an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Monday, January 13th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $36.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.